An estimation of the prevalence of diabetes mellitus in Norway. A prescription registration study.

Scand J Prim Health Care

Department of Pharmacotherapeutics, University of Oslo, Norway.

Published: November 1988

A prevalence of 0.9% for drug-treated diabetes mellitus was calculated (male 0.8; female 1.0) for Norway, based upon a survey of 6777 prescriptions of antidiabetic drugs at 61.5% of Norwegian pharmacies during a four-week period in 1984. A male dominance was found below the age of 50 years, gradually shifting towards female dominance among the elderly. These findings are in accordance with a population screening on diabetes mellitus in the county of Nord-Trøndelag, and may indicate that prescription data can be a valuable source in the estimation of sex and age prevalence figures. Compared to screening, prescription studies are more simple to perform and cheaper, and can provide valuable background information in primary health care.

Download full-text PDF

Source
http://dx.doi.org/10.3109/02813438809009323DOI Listing

Publication Analysis

Top Keywords

diabetes mellitus
12
estimation prevalence
4
prevalence diabetes
4
mellitus norway
4
norway prescription
4
prescription registration
4
registration study
4
study prevalence
4
prevalence 09%
4
09% drug-treated
4

Similar Publications

Background: People with type 2 diabetes mellitus (T2DM) commonly report a higher fatigue intensity than the general population. However, effective fatigue management is lacking because little is known about other fatigue characteristics, including timing, distress, and quality, as well as the potential fatigue subtypes experienced in people with T2DM.

Objective: To describe fatigue intensity, timing, distress, and quality, and identify fatigue subtypes in people with T2DM.

View Article and Find Full Text PDF

Purpose: Women with gestational diabetes (GDM) have increased risk of hypertensive disorders in pregnancy (HDP). However, knowledge remains limited for women with high-risk metabolic profiles, regardless of GDM diagnosis. This study aimed to evaluate the prevalence of HDP among women at high risk for GDM, while simultaneously identifying potential predictive clinical risk factors of HDP.

View Article and Find Full Text PDF

Cardiovascular Outcomes in Patients with Complex Type 2 Diabetes Mellitus Treated with the Dual SGLT Inhibitor Sotagliflozin: A Meta-analysis.

Diabetes Ther

January 2025

The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.

Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.

View Article and Find Full Text PDF

Purpose: To compare the amplitudes and implicit times of the oscillatory (OPs) of the full-field electroretinograms (ERGs) to those of the 30 Hz flicker ERGs in differentiating eyes with diabetic retinopathy (DR) from normal eyes.

Study Design: Single-center observational study.

Methods: Full-field ERGs were recorded in 55 patients with Type 2 diabetes mellitus (DM) and 20 normal control subjects.

View Article and Find Full Text PDF

To evaluate the management and costs of severe hypoglycemia (SH) in children and adolescents with type 1 diabetes (T1D) in our Belgian tertiary pediatric care center. In the EPI-GLUREDIA study, clinical parameters from children and adolescents with T1D were retrospectively analyzed from July 2017 to June 2024. The characteristics of SH and its treatment were collected during the medical consultation following the SH episode.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!